Rating Change
Wedbush reiterated its Outperform rating on Zenas BioPharma, Inc. (NASDAQ:ZBIO) on August 14, 2026.
reiterateNASDAQ:ZBIO
Wedbush Reiterates Outperform Rating on Zenas BioPharma, Inc. (ZBIO)
Wedbush reiterated its Outperform rating on Zenas BioPharma, Inc. (NASDAQ:ZBIO) on August 14, 2026.
At publication ·
What changed
Zenas BioPharma, Inc. (NASDAQ:ZBIO) · reiterate
- Firm
- Wedbush
- Rating
- Outperform to Outperform
- Price at event
- $30.12
- Market capitalization
- $1.7B
At a glance
Key takeaways
- Wedbush reiterated an Outperform rating on Zenas BioPharma (ZBIO) on August 14, 2026, with the stock trading at $30.12 and a market capitalization of $1.7 billion.
Market Context
Zenas BioPharma, Inc. operates in the Healthcare sector. The stock currently trades at $30.12 with a market capitalization of $1.7B.
Analyst coverage from Wedbush provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Zenas BioPharma, Inc.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Zenas BioPharma, Inc.
Among the 10 most recent ratings: 7 Buy, 3 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 14, 2026 | Wedbush | Outperform | N/A |
| Aug 14, 2026 | Guggenheim | Buy | N/A |
| May 15, 2026 | HC Wainwright & Co. | Buy | N/A |
| May 14, 2026 | Morgan Stanley | Equal-Weight | N/A |
| Mar 17, 2026 | Guggenheim | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View ZBIO Stock Page
Frequently Asked Questions
What does the Outperform rating mean for ZBIO?
A rating of Outperform from Wedbush reflects the analyst's outlook on Zenas BioPharma, Inc. (NASDAQ:ZBIO). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ZBIO forecast page.